Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma

In this first-in-human, investigator-initiated, open-label study, three participants with recurrent glioblastoma were treated with CARv3-TEAM-E T cells, which are chimeric antigen receptor (CAR) T cells engineered to target the epidermal growth factor receptor (EGFR) variant III tumor-specific antig...

Full description

Saved in:

Bibliographic Details
Published in:	The New England journal of medicine Vol. 390; no. 14; pp. 1290 - 1298
Main Authors:	Choi, Bryan D., Gerstner, Elizabeth R., Frigault, Matthew J., Leick, Mark B., Mount, Christopher W., Balaj, Leonora, Nikiforow, Sarah, Carter, Bob S., Curry, William T., Gallagher, Kathleen, Maus, Marcela V.
Format:	Journal Article
Language:	English
Published:	United States Massachusetts Medical Society 11.04.2024
Series:	Brief Report
Subjects:	Allergy Antigens Biopsy Brain cancer Brain Tumor Catheters CD8-Positive T-Lymphocytes - metabolism Chemotherapy Chimeric antigen receptors Clinical outcomes Epidermal growth factor receptors ErbB Receptors - antagonists & inhibitors ErbB Receptors - genetics ErbB Receptors - metabolism Genetics Genetics General Glioblastoma Glioblastoma - pathology Glioblastoma - therapy Glioma Hematology Humans Immunology Immunotherapy Immunotherapy, Adoptive - adverse effects Lymphocytes Lymphocytes T Magnetic resonance imaging Neoplasm Recurrence, Local - therapy Neurology Neuroscience Neurosurgery Oncology Radiation Receptors, Antigen, T-Cell - genetics Receptors, Antigen, T-Cell - therapeutic use Receptors, Chimeric Antigen - therapeutic use T-Cells Teams Toxicity Treatments in Oncology Tumors
ISSN:	0028-4793, 1533-4406, 1533-4406
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!